• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Boston, N.J., Bay area lead nation’s top 16 life sciences clusters, all are growing

Report: Boston, N.J., Bay area lead nation’s top 16 life sciences clusters, all are growing

December 5, 2011
CenterWatch Staff

Move over Boston, New Jersey and the San Francisco Bay area. Los Angeles and the Washington, D.C., region are quickly gathering steam as established life sciences hubs. And Minneapolis, Chicago, Denver, Houston, Florida, Atlanta and Indianapolis are among the emerging hubs not far behind. 

That’s according to a new study by Jones Lang LaSalle, a financial and professional services firm specializing in real estate, which recently conducted research to identify the top markets for real estate expansion among life sciences companies. The firm’s first annual Life Sciences Cluster Report ranked 16 emerging and established life sciences clusters in order to gauge where companies in the industry are positioning their facilities to gain competitive advantage. 

Richard McBlaine, principal of solutions development in life sciences at Jones Lang LaSalle, said one of the surprises in the data was that all clusters seem to be growing, instead of one area growing at the expense of others.  

“There was simultaneous growth among many of the emerging clusters and the established clusters,” he said. “That told us: they’re really competing more on their ability to create innovation rather than just their cost base.” 

For companies looking to maximize their dollars when it comes to real estate, the emerging markets are key, said McBlaine, as square footage is cheaper. At the same time, though, locating there is a risk, since much of the knowledge base and venture capital are centered around the more developed clusters. 

“There’s a balance,” he said. “It’s a trade-off to go somewhere in Florida or to Denver, where you can get a lot more space and then spend more of your dollars on discovery, versus being in the top markets where the burn rate is quicker.”  

Added Bill Barrett, executive managing director of life sciences at Jones Lang LaSalle, a life sciences cluster typically develops as a result of a geographic region’s educated workforce, venture capital and economic development incentives, industry-friendly political structures, patent protection laws and ties to universities. 

Though market activity is picking up in most clusters, the report indicates speculative construction continues to be rare in nearly all clusters. Nevertheless, several companies are working on large-scale, build-to-suit projects, signaling a long-term commitment to their respective clusters. These include Astellas’ 445,000-square-foot headquarters project in Chicago, GlaxoSmithKline’s $81 million, 205,000-square-foot headquarters in Philadelphia and Biogen’s 497,000-square-foot headquarters in Cambridge, Mass. 

The report’s cluster rankings were based on a composite score made up of the percentage of total employment in high-tech research and hospital/medical fields; the number of science and engineering graduate students; the distribution of National Institutes of Health (NIH) funding; venture capital funding; R&D spend as a percentage of the region’s total state GDP; and square footage of academic and research facilities. 

Jones Lang LaSalle defines the life sciences as pharmaceuticals, biotechnology, medical device technology, agricultural biotechnology and biofuels. 

The report also looked at international markets emerging as the places to be for life sciences companies. Top markets include Canada, Brazil and Puerto Rico. Some of this is a direct result of governments pledging money for life sciences office parks and facilities.  

“Internationally, we see countries like Brazil and China trying to buy their way into the market by building the parks,” said McBlaine. “They are trying to buy that tipping point. It’s too early yet to say whether or not that’s working.” 

Suz Redfearn 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing